UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 
FORM 8-K
 
 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 
 

Date of Report (Date of the earliest event reported)

July 30, 2015

 
 
 
ULTRALIFE CORPORATION
(Exact name of registrant as specified in its charter)
 
 
 
Delaware 000-20852 16-1387013
(State of incorporation) (Commission File Number) (IRS Employer Identification No.)
 
2000 Technology Parkway, Newark, New York 14513
(Address of principal executive offices) (Zip Code)
 
(315) 332-7100
(Registrant’s telephone number, including area code)
 
 
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
       
 
 

Item 2.02 Results of Operations and Financial Condition

NEWARK, N.Y. – July 30, 2015 -- Ultralife Corporation (NASDAQ: ULBI) reported operating income of $0.8 million on revenue of $19.0 million for the quarter ended June 28, 2015. For the second quarter of 2014, the Company reported an operating loss of $1.3 million on revenue of $15.2 million.

 

“Our second quarter results demonstrate the operating leverage inherent in our business model and the success of our strategy to invest in new products, customers, markets and geographies. Following a strong first quarter performance, we delivered another quarter of 25% revenue growth, substantial gains in profitability marked by a consolidated gross margin of 31%, an operating margin of 4.3%, and an EPS of $0.05,” Michael D. Popielec, Ultralife's President and Chief Executive Officer. “At the mid-point of the year with revenue growth of 25% and EPS improvement of $0.23 over the first half of 2014, we have increasing confidence in our outlook for top-line growth and profitable results for 2015.”

 

Revenue grew 25%, or $3.8 million, to $19.0 million from $15.2 million for the second quarter of 2014 driven by gains in Battery & Energy Product sales. Battery & Energy Products sales were $16.0 million, compared to $12.2 million last year, a 31% increase, primarily due to higher shipments to Government/Defense customers. Communications Systems sales were $3.0 million, flat with the same period last year.

 

Gross profit grew 39% to $5.9 million from $4.2 million for the second quarter a year ago. As a percentage of revenue, gross profit increased 320 basis points to 30.9% from 27.7% last year, primarily reflecting favorable mix of higher gross margin products and improved overhead absorption on higher sales volumes. Battery & Energy Products’ gross margin was 28.4%, compared to 23.6% last year, an increase of 480 basis points. Communications Systems’ gross margin was 44.2%, compared to 44.0% last year, an increase of 20 basis points.

 

Operating expenses declined 9%, or $0.5 million, to $5.0 million from $5.5 million a year ago. As a percentage of revenue, operating expenses were 26.6%, compared to 36.4% a year ago.

 

Higher revenue combined with the leverage of improved gross margin and lower operating expenses resulted in operating income of $0.8 million, compared to an operating loss of $1.3 million for the second quarter of 2014, an improvement of $2.1 million. Operating margin was 4.3%, compared to (8.7)% for the year-earlier period.

 

Net income from continuing operations was $0.8 million, or $0.05 per share, compared to a net loss of $1.4 million, or $0.08 per share, for the second quarter of 2014.

 

The information set forth in this Form 8-K and the attached exhibit is being furnished to and not filed with the Securities and Exchange Commission and shall not be deemed to be incorporated by reference in any filing under the Securities Exchange Act of 1934, as amended, or the Securities Act of 1933, as amended, except to the extent specifically provided in any such filing.

  

 Item 9.01 Financial Statements, Pro Forma Financials and Exhibits

(a)        Exhibits 

              99.1 Press Release of Ultralife Corporation dated July 30, 2015.

 
 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  ULTRALIFE CORPORATION
   
July 30, 2015 By: /s/ Philip A. Fain
    Chief Financial Officer and Treasurer

 



Exhibit 99.1 

Company Contact: Investor Relations Contact:

Ultralife Corporation LHA

Philip A. Fain Jody Burfening

(315) 332-7100 (212) 838-3777

pfain@ulbi.com jburfening@lhai.com

 

 

 

Ultralife Corporation Reports Second Quarter Results

 

 

NEWARK, N.Y. – July 30, 2015 -- Ultralife Corporation (NASDAQ: ULBI) reported operating income of $0.8 million on revenue of $19.0 million for the quarter ended June 28, 2015. For the second quarter of 2014, the Company reported an operating loss of $1.3 million on revenue of $15.2 million.

 

“Our second quarter results demonstrate the operating leverage inherent in our business model and the success of our strategy to invest in new products, customers, markets and geographies. Following a strong first quarter performance, we delivered another quarter of 25% revenue growth, substantial gains in profitability marked by a consolidated gross margin of 31%, an operating margin of 4.3%, and an EPS of $0.05,” Michael D. Popielec, Ultralife's President and Chief Executive Officer. “At the mid-point of the year with revenue growth of 25% and EPS improvement of $0.23 over the first half of 2014, we have increasing confidence in our outlook for top-line growth and profitable results for 2015.”

 

Second Quarter 2015 Financial Results

 

Revenue grew 25%, or $3.8 million, to $19.0 million from $15.2 million for the second quarter of 2014 driven by gains in Battery & Energy Product sales. Battery & Energy Products sales were $16.0 million, compared to $12.2 million last year, a 31% increase, primarily due to higher shipments to Government/Defense customers. Communications Systems sales were $3.0 million, flat with the same period last year.

 

Gross profit grew 39% to $5.9 million from $4.2 million for the second quarter a year ago. As a percentage of revenue, gross profit increased 320 basis points to 30.9% from 27.7% last year, primarily reflecting favorable mix of higher gross margin products and improved overhead absorption on higher sales volumes. Battery & Energy Products’ gross margin was 28.4%, compared to 23.6% last year, an increase of 480 basis points. Communications Systems’ gross margin was 44.2%, compared to 44.0% last year, an increase of 20 basis points.

 

Operating expenses declined 9%, or $0.5 million, to $5.0 million from $5.5 million a year ago. As a percentage of revenue, operating expenses were 26.6%, compared to 36.4% a year ago.

 

 
 

Higher revenue combined with the leverage of improved gross margin and lower operating expenses resulted in operating income of $0.8 million, compared to an operating loss of $1.3 million for the second quarter of 2014, an improvement of $2.1 million. Operating margin was 4.3%, compared to (8.7)% for the year-earlier period.

 

Net income from continuing operations was $0.8 million, or $0.05 per share, compared to a net loss of $1.4 million, or $0.08 per share, for the second quarter of 2014.

 

 

Share Repurchase Program

 

During the second quarter Ultralife repurchased 1,398,454 shares under its 3.4 million share repurchase program, which will end April 30, 2016. Since the inception of the share repurchase program on May 1, 2014, the Company has repurchased 1,941,691 shares.

 

 

About Ultralife Corporation

 

Ultralife Corporation serves its markets with products and services ranging from power solutions to communications and electronics systems. Through its engineering and collaborative approach to problem solving, Ultralife serves government, defense and commercial customers across the globe.

 

Headquartered in Newark, New York, the Company's business segments include Battery & Energy Products and Communications Systems. Ultralife has operations in North America, Europe and Asia. For more information, visit www.ultralifecorporation.com.

 

 

Conference Call Information

 

Ultralife will hold its second quarter earnings conference call today at 10:00 AM ET. To participate in the live call, please dial (800) 915-4836 at least ten minutes before the scheduled start time, identify yourself and ask for the Ultralife call. A live webcast of the conference call will be available to investors in the Events & Presentations section of the Company's website at http://investor.ultralifecorporation.com. For those who cannot listen to the live broadcast, a replay of the webcast will be available shortly after the call at the same location.

 

 
 

This press release may contain forward-looking statements based on current expectations that involve a number of risks and uncertainties. The potential risks and uncertainties that could cause actual results to differ materially include potential reductions in U.S. military spending, uncertain global economic conditions and acceptance of our new products on a global basis. The Company cautions investors not to place undue reliance on forward-looking statements, which reflect the Company's analysis only as of today's date. The Company undertakes no obligation to publicly update forward-looking statements to reflect subsequent events or circumstances. Further information on these factors and other factors that could affect Ultralife's financial results is included in Ultralife's Securities and Exchange Commission (SEC) filings, including the latest Annual Report on Form 10-K. 

 
 

 

ULTRALIFE CORPORATION AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
(Dollars in Thousands)
(unaudited)
       
ASSETS
    June 28,    December 31, 
    2015    2014 
Current assets:          
    Cash and cash equivalents  $15,932   $17,866 
    Trade accounts receivable, net   11,293    11,295 
    Inventories   24,000    26,086 
    Prepaid expenses and other current assets   1,412    1,603 
          Total current assets   52,637    56,850 
           
Property, equipment and improvements, net   9,501    9,812 
Goodwill, intangibles and other assets   20,797    20,980 
          Total assets  $82,935   $87,642 
      
LIABILITIES AND SHAREHOLDERS' EQUITY
Current liabilities:          
    Accounts payable  $6,353   $6,996 
    Accrued compensation and related benefits   2,388    1,725 
    Accrued expenses and other current liabilities   1,865    2,490 
           Total current liabilities   10,606    11,211 
Deferred income taxes and other non-current liabilities   4,628    4,518 
           Total liabilities   15,234    15,729 
           
Shareholders' equity:          
    Common stock   1,897    1,894 
    Capital in excess of par value   176,249    175,940 
    Accumulated deficit   (95,599)   (96,920)
    Accumulated other comprehensive loss   (401)   (467)
    Treasury stock   (14,307)   (8,420)
          Total Ultralife equity   67,839    72,027 
    Noncontrolling interest   (138)   (114)
          Total shareholders’ equity   67,701    71,913 
           
          Total liabilities and shareholders' equity  $82,935   $87,642 

 

 
 

 

ULTRALIFE CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS
(In Thousands except per share amounts)
(unaudited)
             
   Three month periods ended  Six month periods ended
   June 28,  June 29,  June 28,  June 29,
   2015  2014  2015  2014
Revenues:                    
   Battery & energy products  $15,972   $12,165   $32,248   $26,087 
   Communication systems   2,983    3,034    5,884    4,397 
      Total revenues   18,955    15,199   $38,132   $30,484 
                     
Cost of products sold:                    
   Battery & energy products   11,430    9,289    22,922    19,410 
   Communication systems   1,666    1,698    3,344    2,527 
      Total cost of products sold   13,096    10,987    26,266    21,937 
                     
     Gross profit   5,859    4,212    11,866    8,547 
                     
Operating expenses:                    
  Research and development   1,334    1,560    2,693    2,996 
  Selling, general and administrative   3,708    3,976    7,534    7,971 
     Total operating expenses   5,042    5,536    10,227    10,967 
                     
Operating income (loss)   817    (1,324)   1,639    (2,420)
                     
Interest and other (expense) income, net   28    5    (160)   (58)
Income (loss) from continuing operations before income taxes   845    (1,319)   1,479    (2,478)
Income tax provision   71    57    182    117 
                     
Net income (loss) from continuing operations   774    (1,376)   1,297    (2,595)
Loss from discontinued operations, net of tax   —      —      —      (61)
                     
Net income (loss)   774    (1,376)   1,297    (2,656)
                     
Net loss attributable to non-controlling interest   14    16    24    10 
                     
Net income (loss) attributable to Ultralife  $788   $(1,360)  $1,321   $(2,646)
                     
                     
Net income (loss) per share attributable to Ultralife common shareholders – basic:                    
       Continuing operations  $.05   $(.08)  $.08   $(.15)
       Discontinued operations   —      —          (.00)
          Total  $.05   $(.08)  $.08   $(.15)
                     
Net income per share attributable to Ultralife common shareholders – diluted:                    
       Continuing operations  $.05        $.08      
       Discontinued operations   —                 
          Total  $.05        $.08      
                     
Weighted average shares outstanding – basic   16,557    17,533    16,945    17,523 
Weighted average shares outstanding – diluted   16,597         16,977      

 

Ultralife (NASDAQ:ULBI)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Ultralife Charts.
Ultralife (NASDAQ:ULBI)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Ultralife Charts.